http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sang Jin Lee ),( Jong Kyu Park ),( Hyun Il Seo ),( Koon Hee Han ),( Young Don Kim ),( Woo Jin Jeong ),( Gab Jin Cheon ),( Jae Seok Song ) 대한장연구학회 2013 Intestinal Research Vol.11 No.2
Background/Aims: Gastrointestinal stromal tumors (GIST) in the small intestine are rare and can cause bleeding. The study investigated the clinical characteristics of GIST in the small intestine and to determine the factors related to gastrointestinal bleeding. Methods: We retrospectively evaluated the clinical outcomes of 22 patients with small bowel GIST who were pathologically diagnosed at Gangneung Asan Hospital between March 1997 and August 2012. Results: The median age was 63.5 (38-82) years. Nine patients (40.9%) had gastrointestinal bleeding, five patients (22.7%) had abdominal pain, two patients (9%) had palpable mass. The site of tumor was the duodenum in nine cases (40.9%), jejunum in 7 cases (31.8%), and ileum in six cases (27.3%). Most patients underwent small bowel resection or wedge resection but three patients underwent pancreaticoduodenectomy. Tumor size ranged from 1.6 to 19 cm (median 6.5 cm). The median mitotic rate was 2 (0-50)/50 high power fields (HPF). The median mitotic rate was 2 (0-50)/50 HPF. Five patients (25%) showed recurrence. Gender, aspirin or warfarin use, size and mitotic index of tumor, hospital stay, recurrence and survival were not significantly different between bleeding and non-bleeding group. Bleeding group showed older age, proximal location in small intestine and mucosal ulceration significantly. Conclusions: Small bowel GISTs with bleeding were marked by older age, mucosal ulceration and location of proximal small bowel (duodenum and jejunum) rather than distal small bowel (ileum). (Intest Res 2013;11:113-119)
Cheon, Jae Hee,Kim, Jae Hak,Kim, Bo Young,Kim, Seung Won,Hong, Sung Yi,Eun, Chang Soo,Hong, Seong Soo,Byeon, Jeong-Sik,Kim, Tae Il,Han, Dong Soo,Yang, Suk-Kyun,Lee, Kyoung Ryul,Kim, Won Ho G. Thieme 2009 Hepato-gastroenterology Vol.56 No.90
<P>BACKGROUND/AIMS: Adverse reactions to thiopurines may be predisposed by thiopurine methyltransferase (TPMT) or inosine triphosphate pyrophosphatase (ITPA) gene mutations. METHODOLOGY: We examined the frequencies of TPMT and ITPA gene polymorphisms in 812 Korean patients with inflammatory bowel diseases using denaturing high performance liquid chromatography and direct sequencing. Results: The allele frequencies of TPMT*2, TPMT*3A, TPMT*3B, and TPMT*3C were 0, 0, 0, and 0.010 (17/1624), respectively. For the ITPA polymorphism, 173 subjects were heterozygous and 5 were homozygous for the 94C>A missense mutation (allele frequency of A, 0.113). Moreover, the 87T>C, IVS2+21A>C, and IVS2+53C>T polymorphisms were found in one patient each (1/1624), respectively. Of these, 87T>C and IVS2+53C>T were novel single nucleotide polymorphisms of the ITPA gene whose clinical significance should be further evaluated. CONCLUSIONS: Our data describe TPMT and ITPA gene mutation patterns among Koreans and provide a basis for screening studies to identify patients at high risk for myelotoxicity from thiopurine drugs.</P>
Han, Myoung Sook,Chung, Kun Wook,Cheon, Hyae Gyeong,Rhee, Sang Dal,Yoon, Chang-Hwan,Lee, Moon-Kyu,Kim, Kwang-Won,Lee, Myung-Shik American Diabetes Association 2009 Diabetes Vol.58 No.2
<P><B>OBJECTIVE—</B>Imatinib has been reported to induce regression of type 2 diabetes in chronic leukemia patients. However, the mechanism of diabetes amelioration by imatinib is unknown, and it is uncertain whether imatinib has effects on type 2 diabetes itself without other confounding diseases like leukemia. We studied the effect of imatinib on diabetes in <I>db/db</I> mice and investigated possible mechanism's underlying improved glycemic control by imatinib.</P><P><B>RESEARCH DESIGN AND METHODS—</B>Glucose tolerance and insulin tolerance tests were done after daily intraperitoneal injection of 25 mg/kg imatinib into <I>db/db</I> and C57BL/6 mice for 4 weeks. Insulin signaling and endoplasmic reticulum stress responses were studied by Western blotting. β-Cell mass and apoptotic β-cell number were determined by combined terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL) staining and insulin immunohistochemistry. The in vitro effect of imatinib was studied using HepG2 cells.</P><P><B>RESULTS—</B>Imatinib induced remission of diabetes in <I>db/db</I> mice and amelioration of insulin resistance. Expression of endoplasmic reticulum stress markers in the liver and adipose tissues of <I>db/db</I> mice, such as phospho-PERK, phospho-eIF2α, TRB3, CHOP, and phospho–c-Jun NH<SUB>2</SUB>-terminal kinase, was reduced by imatinib. Insulin receptor substrate-1 tyrosine phosphorylation and Akt phosphorylation after insulin administration were improved by imatinib. Serum aminotransferase levels and hepatic triglyceride contents were decreased by imatinib. Pancreatic β-cell mass was increased by imatinib, accompanied by decreased TUNEL<SUP>+</SUP> β-cell and increased BrdU<SUP>+</SUP> β-cell numbers. Imatinib attenuated endoplasmic reticulum stress in hepatoma cells in vitro.</P><P><B>CONCLUSIONS—</B>Imatinib ameliorated endoplasmic reticulum stress and induced remission of diabetes in <I>db/db</I> mice. Imatinib or related compounds could be used as therapeutic agents against type 2 diabetes and metabolic syndrome.</P>
Spinal Surgery in Patients With End-Stage Renal Disease Undergoing Hemodialysis Therapy
Han, In-Ho,Kim, Keun-Su,Park, Hyeong-Cheon,Chin, Dong-Kyu,Jin, Byung-Ho,Yoon, Young-Sul,Ahn, Jung-Yong,Cho, Yong-Eun,Kuh, Sung-Uk Lippincott Williams Wilkins, Inc. 2009 1528-1159) Vol.34 No.18
STUDY DESIGN.: Case series retrospective review. OBJECTIVE.: To present the surgical treatment guideline for spinal diseases with end-stage renal disease (ESRD) patients undergoing hemodialysis. SUMMARY OF BACKGROUND DATA.: Treatment for spinal diseases with ESRD patients in is a special clinical challenge because of complex medical and clinical problems. METHODS.: We retrospectively reviewed 12 patients who underwent spinal surgeries among patients with chronic renal failure at our hospital from May 2000 to September 2007. The medical records and radiologic findings for these patients were reviewed and concomitant medical diseases, laboratory findings, pre- and postoperative care, clinical outcomes, and complications were investigated. RESULTS.: One patient died of pneumonia and sepsis 2 months after fusion surgery. Other postoperative complications included postoperative delirium in 3 patients and terminal ileitis and delayed primary spondylodiscitis in 1 patient each. There were no postoperative wound infections associated with the spinal surgery.The preoperative mean visual analogue scale score was 7.9 ± 0.61, which improved to 2.2 ± 1.25 at the time of final follow-up for 11 patients. Among 5 patients who underwent fusion surgery, solid bone fusion was achieved in only 3 patients and included those who underwent posterior lumbar interbody fusion with pedicle screw fixation. In 2 patients who underwent posterior lumbar interbody fusion with cage alone, solid fusion was not achieved. In 1 of 2 patients who underwent anterior cervical fusion with plating, solid fusion was achieved. The overall fusion rate was 57.1% in patients with ESRD undergoing hemodialysis. CONCLUSION.: Spinal surgeries in ESRD patients undergoing hemodialysis can be performed with acceptable outcomes; however, the complication rates and mortality rates are relatively high and the fusion rate is low. To obtain a better outcome, multiple factors such as comorbid medical diseases, laboratory abnormalities, and osteoporosis should be carefully considered.
Effects of bee venom treatment on growth performance of young pigs.
Han, Sang Mi,Lee, Kwang Gill,Yeo, Joo Hong,Hwang, Sung Jin,Jang, Chul Ho,Chenoweth, Peter J,Pak, Sok Cheon Institute for Advanced Research in Asian Science a 2009 The American journal of Chinese medicine Vol.37 No.2
<P>This study examined the effect of whole bee venom (BV) as a potential stimulant of the piglet immune system, on growth performance, blood parameters, plasma protein and immune globulin content of serum. Piglets (n = 97) received combinations of 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg of parenterally administered BV on 4 occasions between birth and Day 30. In the apipuncture group (n = 31), piglets were acupunctured with the worker honeybee. Two acupoints, GV-1 (Jiao-chao) and GV-20 (Bai-hui), were selected for apipuncture. All piglets (n = 128) in the treatment groups were treated 4 times throughout the study period of 60 days. The control piglets received no treatments. Blood was taken via jugular venipuncture on Day 30 after birth. Body weight and survivability were measured, and changes in hematological values were analyzed. Both the BV injection group and apipuncture group increased body weight and survivability by 26.6% and 21.8%, and 7.9% and 6.7% respectively compared to the controls. The numbers of leukocytes, erythrocytes, lymphocytes and monocytes were not influenced by treatments. However, a potential clinical benefit of high dose therapy was seen in increased populations of leukocytes, lymphocytes and monocytes compared with either the apipuncture or control groups. Other blood parameters such as total protein and albumin were not affected by treatment. However, IgG levels were generally higher in treated groups than in the controls. These findings indicate that BV might be useful to stimulate immuno-competence in pig production, possibly via the primary bioactive components of melittin, phospholipase A(2) and apamin. The administration of BV, either via injection or acupuncture, did not make any differences in growth performance of young pigs. These results would be useful for further purification and characterization of immune boosting agents from BV.</P>